Below are the most recent publications written about "Ovarian Neoplasms" by people in Profiles.
-
Ghisoni E, Benedetti F, Minasyan A, Desbuisson M, Cunnea P, Grimm AJ, Fahr N, Capt C, Rayroux N, De Carlo F, Gulhan DC, Dagher J, Barras D, Morotti M, Mar?n-Jim?nez JA, Chap BS, Santoro T, Spagnol G, Fleury M, Fortis K, Dorier J, Townsend MK, Tissot S, Rusakiewicz S, Ferreira HJ, Kraemer AI, Bassani-Stenberg M, Swisher EM, Kandalaft LA, Mastroyannis SA, Montone KT, Powell DJ, Banerjee S, Terry KL, Tworoger SS, Pittet MJ, Tanyi JL, Coukos G, Merritt MA, Fotopoulou C, Conejo-Garcia JR, Laniti DD. Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer. Cancer Cell. 2025 Aug 11; 43(8):1568-1586.e10.
-
McLoughlin K, Merritt MA. Opportunistic salpingectomy for prevention of ovarian cancer among the general population. Curr Opin Obstet Gynecol. 2025 Oct 01; 37(5):340-345.
-
Wamba BEN, Mondal T, Freenor V F, Shaheed M, Pang O, Bedinger D, Legembre P, Devel L, Bhatnagar S, Leiserowitz GS, Tushir-Singh J. Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapy. Nat Commun. 2025 Jul 01; 16(1):5748.
-
Fu Z, Borho L, Taylor SE, Kelemen LE, DeFazio A, Webb PM, K?bel M, Meagher NS, Na R, Antoniou AC, Brand AH, Kennedy CJ, Nevins N, Pharoah PDP, Shvetsov YB, Winham SJ, Alsop J, Beckmann MW, Bolithon A, Boros J, Bowtell DDL, Brenton JD, Carney ME, Chudecka-Glaz A, Cook LS, Cybulski C, Fasching PA, Fereday S, Fortner RT, Garc?a MJ, Goode EL, Goodman MT, Gronwald J, Hartmann A, Hernandez BY, H?gdall E, Huntsman DG, Jensen A, Jimenez-Linan M, Joseph JM, Karlan BY, Kaznowska E, Kjaer SK, Kluz T, Koziak JM, Lester J, Longacre TA, Lycke M, McGuire V, Moysich KB, Murphy RA, Orsulic S, Ramus SJ, Rodr?guez-Antona C, Rothstein JH, Samra S, Sieh W, Steed H, Sundfeldt K, Talhouk A, Ucinski J, Wang C, Wentzensen N, Whittemore AS, Wilkens LR, Songer T, Brooks MM, Tang L, Modugno F. Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis. Gynecol Oncol. 2025 Jul; 198:112-129.
-
Rivera-Serrano M, Flores-Col?n M, Valiyeva F, Mel?ndez LM, Vivas-Mej?a PE. Upregulation of MMP3 Promotes Cisplatin Resistance in Ovarian Cancer. Int J Mol Sci. 2025 Apr 24; 26(9).
-
Li H, Chatla S, Liu X, Tian Z, Vekariya U, Wang P, Kim D, Octaviani S, Lian Z, Morton G, Feng Z, Yang D, Sullivan-Reed K, Childers W, Yu X, Chitrala KN, Madzo J, Skorski T, Huang J. ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination. Cancer Lett. 2025 Mar 31; 613:217505.
-
Alday-Monta?ez FD, Dickens-Terrazas D, Mejia-Carmona GE, Robles-Escajeda E, Kirken RA, Bencomo-Alvarez AE, Carrasco-Urrutia VJ, Lobo-Galo N, Plenge-Tellechea LF, Diaz-Sanchez ?G, Mart?nez-Mart?nez A. Pathogenic variants in BRCA1 and BRCA2 genes associated with female breast and ovarian cancer in the Mexican population. J Med Life. 2025 Jan; 18(1):38-47.
-
Merritt MA, Abe SK, Islam MR, Rahman MS, Saito E, Katagiri R, Shin A, Choi JY, Le Marchand L, Killeen JL, Gao YT, Tamakoshi A, Koh WP, Sakata R, Sawada N, Tsuji I, Sugawara Y, Kim J, Park SK, Kweon SS, Shu XO, Kimura T, Yuan JM, Tsugane S, Kanemura S, Lu Y, Shin MH, Wen W, Ahsan H, Boffetta P, Chia KS, Matsuo K, Qiao YL, Rothman N, Zheng W, Inoue M, Kang D. Reproductive factors and risk of epithelial ovarian cancer: results from the Asia Cohort Consortium. Br J Cancer. 2025 Mar; 132(4):361-370.
-
Carey KM, Young CD, Clark AJ, Dammer EB, Singh R, Lillard JW. Subtype-specific analysis of gene co-expression networks and immune cell profiling reveals high grade serous ovarian cancer subtype linkage to variable immune microenvironment. J Ovarian Res. 2024 Dec 03; 17(1):240.
-
Nelson BH, Hamilton P, Phung MT, Milne K, Harris B, Thornton S, Stevens D, Kalaria S, Singh K, Laumont CM, Moss E, Alimujiang A, Meagher NS, Bolithon A, Fereday S, Kennedy CJ, Hendley J, Ariyaratne D, Alsop K, Traficante N, Goode EL, Karnezis A, Shen H, Richardson J, McKinnonDeurloo C, Chase A, Grout B, Doherty JA, Harris HR, Cushing-Haugen KL, Anglesio M, Heinze K, Huntsman D, Talhouk A, Hanley GE, Alsop J, Jimenez-Linan M, Pharoah PD, Boros J, Brand AH, Harnett PR, Sharma R, Hecht JL, Sasamoto N, Terry KL, Karlan B, Lester J, Carney ME, Goodman MT, Hernandez BY, Wilkens LR, Behrens S, Turzanski Fortner R, Fasching PA, Bisinotto C, Candido Dos Reis FJ, Ghatage P, K?bel M, Elishaev E, Modugno F, Cook L, Le N, Gentry-Maharaj A, Menon U, Garc?a MJ, Rodriguez-Antona C, Farrington K, Kelemen LE, Kommoss S, Staebler A, Garsed DW, Brenton JD, Piskorz AM, Bowtell DD, DeFazio A, Ramus SJ, Pike MC, Pearce CL. Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer. J Clin Invest. 2024 Oct 29; 134(24).